Go Deep
Roivant Sciences Ltd.
Roivant Sciences Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,947 | -63.4 | 5.74 | 0.02 | 3,192.13 |
| Oct 2026 | 17,861 | -64.2 | 5.81 | 0.02 | 3,232.47 |
| Oct 2026 | 17,965 | -63.3 | 5.72 | 0.02 | 3,175.79 |
| Oct 2026 | 17,725 | -65.5 | 5.92 | 0.02 | 3,290.13 |
| Oct 2026 | 17,680 | -65.9 | 5.96 | 0.02 | 3,310.99 |
| Oct 2026 | 17,295 | -69.4 | 6.28 | 0.02 | 3,480.62 |
| Oct 2026 | 17,162 | -70.7 | 6.39 | 0.02 | 3,534.94 |
Roivant Sciences Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,442,000.0 | 2,520,000.0 | 1,999,000.0 | 1,571,000.0 |
| Net Profit | -189,837,000.0 | 302,994,000.0 | -265,891,000.0 | -113,519,000.0 |
| EPS | -0.3 | 0.4 | -0.4 | -0.2 |
Roivant Sciences Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 8,260,000.0 | 29,053,000.0 | 32,713,000.0 | 31,530,000.0 | — |
| Net Profit | -299,771,000.0 | -171,981,000.0 | 4,348,926,000.0 | -1,009,030,000.0 | — |
| EPS | -0.4 | -0.2 | 5.2 | -1.4 | — |
Roivant Sciences Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 5,708,687,000.0 | 5,436,940,000.0 | 7,222,482,000.0 | 2,389,604,000.0 | — |
| Total Liabilities | 416,275,000.0 | 249,742,000.0 | 773,953,000.0 | 782,017,000.0 | — |
| Total Equity | 4,527,370,000.0 | 4,687,605,000.0 | 5,968,581,000.0 | 1,157,766,000.0 | — |
Owes vs Owns
Roivant Sciences Ltd. owed $0.07 for every $1 it owned in Jun 2026, down from $0.33 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.07× | 0.05× | 0.11× | 0.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Roivant Sciences Ltd. Assets & Liabilities Breakdown (USD millions)
What it owns — Mar 2026
Cash & short-term investments 75.2%Receivables 13.5%Fixed assets (tangible) 1.6%Long-term investments 7.1%Other assets 2.6%
How it's funded — Mar 2026
Long-term debt 1.7%Other liabilities 5.1%Shareholders' equity 92.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 4,291.8 | 4,886.9 | 6,495.0 | 1,676.8 |
| Receivables | 770.2 | 0.0 | 82.8 | 37.6 |
| Inventory | 0.0 | 0.0 | 35.3 | 2.8 |
| Fixed assets (tangible) | 92.4 | 101.1 | 59.3 | 92.3 |
| Intangible assets | 0.0 | 0.0 | 137.8 | 144.9 |
| Long-term investments | 408.0 | 302.9 | 247.8 | 304.3 |
| Other assets | 146.2 | 146.0 | 164.5 | 130.9 |
| Liabilities & equity | ||||
| Short-term debt | 11.1 | 9.8 | 12.0 | 40.7 |
| Long-term debt | 96.3 | 90.3 | 430.6 | 375.5 |
| Payables | 18.0 | 23.7 | 14.0 | 37.8 |
| Other liabilities | 290.8 | 125.9 | 317.3 | 328.0 |
| Shareholders' equity | 5,292.4 | 5,187.2 | 6,448.5 | 1,607.6 |
| Net tangible assets | 4,527.4 | 4,687.6 | 5,968.6 | 1,012.9 |
Roivant Sciences Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -750,349,000.0 | -839,451,000.0 | -765,268,000.0 | -843,393,000.0 | — |
| Investing Activities | -682,333,000.0 | -1,766,291,000.0 | 5,203,623,000.0 | -44,269,000.0 | — |
| Financing Activities | 134,236,000.0 | -1,219,794,000.0 | 419,364,000.0 | 499,462,000.0 | — |